Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 901–1,000 of 1,000
Cimetidine-Based Cationic Amphiphiles for In Vitro Gene Delivery Targetable to Colon Cancer
Manturthi, S., Bhattacharya, D., Sakhare, K. R., Narayan, K. P., & Patri, S. V. (2022) · ACS Omega · doi:10.1021/acsomega.2c03777 · Cited by 5
What Surgeons Need to Know About Gene Therapy for Cancer
Sivarajah, S., Emerick, K. S., & Kaufman, H. L. (2022) · Advances in Surgery · doi:10.1016/j.yasu.2022.02.006 · Cited by 3
Daele, L. V., Cid, Í. A., Vereecken, S., Neyts, K., Strubbe, F., & Dubruel, P. (2023) · European Polymer Journal · doi:10.1016/j.eurpolymj.2023.112537 · Cited by 3
Artificial Intelligence-Mediated Computer-Aided Design of Viral Gene Therapies
Daneshvar, A., & Lukianov, S. N. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0014 · Cited by 3
“87 In addition, computational models can facilitate the prediction of immunogenicity and guide the design of viral vectors with lower immunogenic profiles, thereby reducing the risk of adverse immune responses.”
InfluentialIntegrated Process and Supply Chain Design and Optimization
Triantafyllou, N., Sarkis, M., Shah, N., Kontoravdi, C., & Papathanasiou, M. M. (2023) · Cell engineering · doi:10.1007/978-3-031-45669-5_7 · Cited by 2
The formation and architecture of surface-initiated polymer brush gene delivery complexes
Neri-Cruz, C. E., Chang, L., Teixeira, F. M. E., Hakobyan, S., Gutfreund, P., Campana, M., Zarbakhsh, A., & Gautrot, J. E. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.12.207 · Cited by 3
Grošelj, U., Kavčič, M., Torkar, A. D., Kafol, J., Lainšček, D., Jerala, R., Sever, M., Zver, S., Serša, G., Čemažar, M., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03828-8 · Cited by 5
“However, it’s crucial to acknowledge that gene therapy has occasionally been associated with risks and potential side effects [14, 28, 29].”
Off-target detection of CRISPR-Cas9 nuclease in vitro with CROFT-Seq
Toliusis, P., Grybauskas, A., Šinkūnas, T., Karvelis, T., Sasnauskas, G., & Zaremba, M. (2026) · Synthetic Biology · doi:10.1093/synbio/ysag006 · Cited by 2
“Programmable genome editing nucleases, such as CRISPR-Cas9, hold great promise for therapeutic applications and have attracted widespread attention from the scientific community [1–3].”
Uchiumi, F. (2018) · InTech eBooks · doi:10.5772/intechopen.71701 · Cited by 4
La respuesta a proteínas mal plegadas como blanco terapéutico en la enfermedad de Alzheimer
Rivera-Krstulović, C., & Duran-Aniotz, C. A. (2020) · Revista médica de Chile · doi:10.4067/s0034-98872020000200216 · Cited by 7
Genetic services diffusion in the precision medicine ecosystem
Wadovski, R. C. B., Nogueira, A. R. R., & Chimenti, P. C. P. D. S. (2020) · International Journal of Pharmaceutical and Healthcare Marketing · doi:10.1108/ijphm-02-2019-0010 · Cited by 3
Shen, C., Lin, M.-C., Fang, C., Chen, P., Chou, C.-C., Tung, C., Chao, C., Chang, D., & Wang, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00280-8 · Cited by 3
Stem Cell Therapies for Cardiovascular Diseases: What Does the Future Hold?
Chen, H.-Y., Strappe, P., & Wang, L. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.12.001 · Cited by 3
The sneaking ligand approach for cell type-specific modulation of intracellular signalling pathways
Sehnert, B., Burkhardt, H., Finzel, S., Dübel, S., & Voll, R. E. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.018 · Cited by 3
Cancer Diagnostics and Therapeutics
Prabhakar, U., Jayalakshmi, Y., & Wang, C. K. (2018) · Bioanalysis · doi:10.1007/978-3-030-01775-0_3 · Cited by 3
Gene-Enhanced Personalized Regenerative Medicine for Bone
Alavian, F., Alizadeh, A., & Ghasemi, S. (2019) · Journal of Applied Biotechnology Reports · doi:10.29252/jabr.06.01.01 · Cited by 3
Genetics and molecular biology
Woolliscroft, J. O. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819620-5.00010-2 · Cited by 3
Combining Nanoparticles with Colloidal Bubbles: A Short Review
Litau, E. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0319-2_27 · Cited by 3
The Role of Gene Therapy in the Treatments of Type 1 Diabetes Mellitus: a review
Smail, H. O. (2020) · Biology Medicine & Natural Product Chemistry · doi:10.14421/biomedich.2020.92.57-64 · Cited by 5
“They show the long-sought-after potential of gene therapy to provide 'cures' after certain potentially terminal or seriously disabled disorders (Naldini, 2015).”
BackgroundChallenges Posed by Gene Manipulations and Sport Performance
Cohen‐Haguenauer, O. (2021) · Springer eBooks · doi:10.1007/978-3-030-79293-0_4 · Cited by 3
Current trends in site and target specific delivery of nanomedicine for gene therapy
Muthuraman, A., Mehdi, S., & Rishitha, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816504-1.00010-7 · Cited by 3
Imaging of Gene and Cell-Based Therapies: Basis and Clinical Trials
Jacobs, A. H., Schelhaas, S., Viel, T., Waerzeggers, Y., Winkeler, A., Zinnhardt, B., & Gelovani, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00060-0 · Cited by 5
Shamoun, M., & Callaghan, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-49980-8_6 · Cited by 3
Conjugated Polymers for Gene Delivery
Moon, J. H., & Kenry, K. (2018) · Wiley eBooks · doi:10.1002/9783527342747.ch8 · Cited by 5
Luo, Y., Wang, Y., Chen, Y., Li, B., Yang, T., Zhao, X., & Ding, P. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106452 · Cited by 2
Optimizing Yeast Homologous Recombination for Splicing Large Coronavirus Genome Fragments
Xiong, G., Huang, X., Hu, A., Meng, Z., Cui, J., Feng, Y., Chen, Z., Lu, Y., Yang, Q., & Liu, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413742 · Cited by 2
Plant Growth-Promoting Rhizobacterial Enzyme Dynamics in Soil Remediation
Mansour, H. A.-G., & El-Hady, M. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-84939-8_12 · Cited by 4
Shamsi, A., Alrouji, M., AlOmeir, O., Tasqeruddin, S., Khuzin, D., & Zuberi, A. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1681891 · Cited by 5
“To achieve this, a variety of virus delivery systems have been used that includes lentiviral vectors (LV), adenoviral vectors (AdV), and adeno-associated viruses (AAV) (Wang et al., 2017, 2019; Naldini, 2015; Daya and Berns, 2008).”
Qie, B., Li, J., Wan, M., & Zhu, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126298 · Cited by 2
Piermarini, E., Guha, S., Qiang, L., Gray‐Edwards, H. L., Sena‐Esteves, M., & Baas, P. W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.029 · Cited by 2
Chen, X., Li, S., Lu, Q., Li, Y., Zhu, M., Zhang, S., Fang, Y., Wen, C., Yang, D., Fan, P.-L., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03852-7 · Cited by 2
“Effective cellular uptake is critical for efficient gene transfection and antitumor effect [24].”
Prime Editing, CRISPR-Cas9, and NanoCas Genome Editing for Cancer Treatment
Hossain, H., Sayeed, S. S. B., Islam, M. S., Ahmad, T., Brishty, K. A., Chowdhury, S. R., Alam, M. S., Mahmud, M. S., & Rahman, M. M. (2026) · Molecular Biotechnology · doi:10.1007/s12033-025-01548-9 · Cited by 6
“Although non-integrating nanoparticles are used in NanoCas systems to assist in reducing this danger, vector-based delivery techniques still carry this risk [183].”
Cell labeling approaches for tracking stromal vascular fraction fate
Dadashizadeh, G., Wojtowicz‐Piotrowski, S., Khalaf, F., Vlavcheski, F., & Jeschke, M. G. (2026) · Methods · doi:10.1016/j.ymeth.2026.03.010 · Cited by 2
Jiang, C., Wang, X., Hui, L. I., Prasad, P. N., & Chen, G. (2026) · PhotoniX Life · doi:10.3724/pxlife.2025-0008 · Cited by 2
Lin, T.-M., Chang, H., Lin, T.-C., Lin, C.-S., Sun, Y., & Lin, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70800 · Cited by 2
“Lentiviral vectors, AAV, CRISPR/Cas9 and emerging editing tools provide the technological means to implement these strategies [53, 54].”
InfluentialTherapeutic modulation of HIV-1 using miRNAs and lncRNAs: from bench to bedside
Zubair, A., Hung, N. M., Waheed, Y., & Afghan, N. (2026) · Virology Journal · doi:10.1186/s12985-026-03175-5 · Cited by 2
“Also, special precautions are needed when using them in HIV patients as they may indulge in drug interactions with the viral replication processes [97, 145].”
RNA ‐centric world of retroviruses: unravelling the molecular strategies of genomic RNA packaging
Jehad, M. A., Prabhu, S., Ali, L. M., Pillai, V. N., Mustafa, F., & Rizvi, T. A. (2026) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1002/brv.70188 · Cited by 3
Vats, S., Shah, D. M., Gul, A., Shreyash, N., Bhatia, K., Mady, M. F., Dabade, S., Tiwary, S. K., Karim, A., & Elzatahry, A. A. F. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.6c00294 · Cited by 2
Dual Gene Delivery Reagents From Antiproliferative Alkylphospholipids for Combined Antitumor Therapy
Gaillard, B., Rémy, J.-S., Pons, F., & Lebeau, L. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.581260 · Cited by 2
“Although non-viral vectors can generally hardly compete with viral ones in terms of transfection efficiencies, they are superior to the latter with regard to production costs, payload size, and safety issues (Naldini, 2015).”
BackgroundPrevention and treatment of gerbil hepatitis E using the programmable CRISPR-Cas13d system
Zhao, C., Li, C., Li, S., Wu, H., Ren, P., Liu, T., Hu, X., & Zhang, R. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.020 · Cited by 4
Abubakar, A. S., George–Opuda, I. M., Anthony, A., Ben-Chioma Adline, E., & Elekima, I. (2024) · Asian Journal of Biochemistry Genetics and Molecular Biology · doi:10.9734/ajbgmb/2024/v16i1354 · Cited by 2
Light-controllable cell-membrane disturbance for intracellular delivery
Huo, W., Miki, K., Mu, H., Osawa, T., Yamaguma, H., Kasahara, Y., Obika, S., Kawaguchi, Y., Hirose, H., Futaki, S., et al. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02956e · Cited by 3
Kaushik, M., Guptha, P. M., Vanangamudi, M., Surendran, V., Ashique, S., Islam, A., Mojgani, N., & Hussain, A. (2024) · Advances in immunology · doi:10.1016/bs.ai.2024.10.008 · Cited by 3
Application of chitosan-based nano-drugs in the treatment of brain diseases
Chen, C., Qi, Y., & Xue, X. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-1164 · Cited by 4
Nanopharmacology Intervention in Human Pathological Diseases
Matai, I., Garg, D., Gupta, U., & Sachdev, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817830-0.00007-2 · Cited by 4
Benyahia, B., Brumano, L. P., Pessoa, A., & da Silva, F. V. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-444-64301-8.00002-0 · Cited by 2
Jäschke, N. M., & Büning, H. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.04.002 · Cited by 2
Montesinos‐Rongen, M., Sánchez-Ruiz, M., Siebert, S., Winter, C., Siebert, R., Brunn, A., & Deckert, M. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0049 · Cited by 2
“This mechanism results in insertions and deletions that are used to disrupt gene function (for a review, see Katti et al 5 and Naldini 6 ).”
Towards routine manufacturing of gene therapy drugs
Merten, O., & Wright, J. F. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.21 · Cited by 3
Gene Editing in Adult Hematopoietic Stem Cells
López-Manzaneda, S., Fañanas-Baquero, S., Nieto-Romero, V., Roman‐Rodriguez, F. J., Fernández-García, M., Pino-Barrio, M. J., Rodríguez-Fornés, F., Díez, B., García-Bravo, M., Navarro, S., et al. (2016) · InTech eBooks · doi:10.5772/62383 · Cited by 2
“Gene therapy has become a feasible and attractive alternative therapeutic strategy for several diseases, from inherited hematopoietic, immune, and nervous diseases, including primary immunodeficiencies, leukodystrophies, thalassemias, hemophilias, and retinal dystrophies to cancer and other malignancies (36).”
Recent advances in cardiac gene therapy strategies targeting advanced heart failure
Chen, C., Seeger, T., Termglinchan, V., & Karakikes, I. (2017) · Continuing Cardiology Education · doi:10.1002/cce2.68 · Cited by 3
“Phase I/II gene therapy clinical trials have shown efficacy and excellent safety records for various severe inherited diseases of the blood, immune and nervous systems, including primary immunodeficiencies, leukodystrophies, thalasaemias, hemophilias, as well as cancer [6].”
BackgroundDesarrollo de vectores génicos basados en polímeros sintéticos: PEI y PDMAEMA
Diaz, I. L., Sierra, C. A., & Pérez-Pérez, L. D. (2018) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v47n3.77370 · Cited by 2
Precision Medicine Using Pharmacogenomic Panel-Testing
van der Wouden, C. H., Guchelaar, H., & Swen, J. J. (2020) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2020.07.012 · Cited by 3
“Opportunely, over the last decades, newly developed drugs have been shifting from unspecific small molecules to more targeted drugs in the form of humanized monoclonal antibodies [100], cell therapies [101], and gene therapies [102] with fewer off-target ADRs.”
BackgroundSuperhelical DNA liquid crystals from dendrimer-induced DNA compaction
Mansel, B. W., Su, C., Chen, C., Young, C.-M., Huang, Y., Yang, C.-C., & Chen, H. (2021) · Soft Matter · doi:10.1039/d1sm00547b · Cited by 2
Liposome: A potential drug delivery vector to treat dementia
Agrawal, M., Roy, U., & Alexander, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824331-2.00010-8 · Cited by 2
Precision Medicine Using Pharmacogenomic Panel-Testing
van der Wouden, C. H., Guchelaar, H., & Swen, J. J. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.09.012 · Cited by 2
Gene delivery and biomedical engineering
Gersbach, C. A. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.11.003 · Cited by 2
A study of adeno-associated virus in cortical-thalamostriatal pathway
Sun, S., Zhu, Z., He, T., Chen, F., Wang, X., Zhang, X., Li, M., Li, Y., Sun, Y., He, Q., et al. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147698 · Cited by 2
Highly Effective Crosslinker for Redox-Sensitive Gene Carriers
Lin, L., Chen, J., Hu, Y., Fang, H., Wang, K., Tian, H., & Chen, X. (2021) · Advances in Polymer Technology · doi:10.1155/2021/5635981 · Cited by 2
Protein Conformational Disease: Visit the Facts at a Glance
Peng, Y., & Alexov, E. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0021868 · Cited by 2
Breaking the Barriers of Genetic and Metabolic Disorders
Büning, H., Bosch, F., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.29093.hbu · Cited by 2
Han, M., Zhao, J., Fabian, J. M., Mustafa, S., Ruan, Y., Wiederman, S. D., & Ebendorff‐Heidepriem, H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.18.996173 · Cited by 3
Vijay, U., Pappu, P., Madduru, D., Stephen, N. B., Suravajhala, P., & Bandapalli, O. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98806-3.00008-8 · Cited by 1
Li, Y., Chen, X., Lv, C., & Cheng, Y. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1148699 · Cited by 1
“, 2014), disease treatment (Naldini, 2015; Stewart et al., 2018) and other fields.”
BackgroundGenomic editing: From human health to the “perfect child”
Iancu, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19045-2.00003-9 · Cited by 2
Gene Therapy of Extracellular Vesicles in Cardiovascular and Metabolic Diseases
Kovács, Á. F. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-1443-2_14 · Cited by 1
Beschorner, N., Künzle, P., Voges, M., Hauber, I., Indenbirken, D., Nakel, J., Virdi, S., Bradtke, P., Lory, N. C., Rothe, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298542 · Cited by 3
Cui, J., Hu, A., Xiong, X.-H., Wang, Q., Chen, Z., Chen, Z., Lu, Y., Xia, X., Chen, H., & Liu, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111514 · Cited by 3
Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene Therapy Insights
Shah, D. D., Chorawala, M. R., Pandya, A. J., Kothari, N. R., Prajapati, B. G., & Parekh, P. S. (2024) · Current Medical Science · doi:10.1007/s11596-024-2936-5 · Cited by 1
“To address this issue, researchers are exploring ways to target therapeutic genes to specific locations in the genome and developing methods to monitor the long-term safety and efficacy of gene therapy [147] .”
Chang, J., Yang, X., Zhang, T., Sun, H., Cheng, H., Jia, Z., Li, Y., Ma, S., Sun, T., & Cao, J. (2025) · Molecules · doi:10.3390/molecules30081811 · Cited by 1
“Early useful gene therapy involved replacing the endogenous defective Molecules 2025 , 30 , 1811 2 of 14 DNA with exogenous “correct” DNA [6,7].”
Application of bacteria-mediated gene therapy in tumor treatment
Feng, R., Du, M., & Chen, Z. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2502638 · Cited by 3
“This process enables the targeted delivery of information-rich gene cassettes and promotes the stable and orderly expression of biological agents [16].”
Recent advances in gene therapy for neurological disorders: A comprehensive overview
Jindal, D. (2025) · Adesh University Journal of Medical Sciences & Research · doi:10.25259/aujmsr_20_2025 · Cited by 3
Gene Therapy and Epigenetic Modulation in Chronic Pain: A Future Without Opioids?
Idahor, C. O., Okorie, M. A., Mokobia, S., Erhuanga, P., Ogbonna, N., Ogunfuwa, O., Etoroma, O. M., Abhulimen, I. J., & Chinedu, E. (2025) · Cureus · doi:10.7759/cureus.94508 · Cited by 2
“One promising example uses HSV (herpes simplex virus) vectors to carry anti-inflammatory molecules like IL-10 into inflamed nerves, and it was shown to reduce nerve pain in animal models without the side effects of pain medications [28].”
Liu, J., Zhang, Z., Polozova, A., Chan, B., Savjani, N., Wypych, J., Rice, Y. Y., Bondarenko, P. V., Semin, D. J., & Nashed-Samuel, Y. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.104045 · Cited by 1
Spherical Polyelectrolyte Brushes for Nonviral Efficient Gene Delivery
Liu, L., Li, Y., Wang, J., Hu, C., Wang, J., & Guo, X. (2025) · ACS Applied Polymer Materials · doi:10.1021/acsapm.5c03696 · Cited by 1
Huang, G., Tang, Y. J., Zhang, S., Ning, H., Xu, J., Li, F., & Zhang, X. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126392 · Cited by 1
Targeting immune heterogeneity in liver metastases through in vivo genetic engineering
Giacca, G., & Squadrito, M. L. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.102012 · Cited by 1
Therapeutic antibody delivery: vector tools to boost efficacy and affordability
Chiyyeadu, A., Khan, B., Ehrhardt, K., Büning, H., Morgan, M. A., & Schambach, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1714390 · Cited by 1
Martilotta, A. (2026) · Revista Científica ANMAT · doi:10.62035/rca.7.88 · Cited by 1
The fetal frontier: A review of current and emerging fetal therapies for genetic diseases
Brown, C. G., Ray, M., Carpenter, M. D., Forde, B., Subramanian, T., Temple, H., Tenguria, S., & Galganski, L. A. (2026) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2026.151583 · Cited by 1
Enhancer-based gene therapy: a new path for precision medicine
Marei, H. E. S. (2026) · Hereditas · doi:10.1186/s41065-026-00655-0 · Cited by 1
Mir, M. Y., Seh, B. A., Rafiq, K., & Légrádi, Á. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062845 · Cited by 1
“Lentiviral vectors offer the advantage of stable genomic integration and sustained transgene expression, making them attractive for chronic neurological disorders requiring long-term modulation [7,8].”
Trischitta, P., Nasiłowska, B., Pennisi, R., Costa, M., Sciortino, M. T., & Kutwin, M. (2026) · Biomolecules · doi:10.3390/biom16040523 · Cited by 2
“Gene therapy has traditionally relied on viral vectors due to their high efficiency in delivering nucleic acids and achieving sustained gene expression [26].”
Gene therapy for aging: Current evidence and future directions
Zhang, Y. C., Gan, L., Wang, S., & Zhang, J. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103144 · Cited by 1
Rajendiran, R., Pathak, S., Kumar, A., Bhaumik, S., Amit, S., Pydi, S. P., & Jayandharan, G. R. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01896 · Cited by 1
Maroun, G., Brondello, J., & Pers, Y. (2026) · Joint Bone Spine · doi:10.1016/j.jbspin.2026.106074 · Cited by 2
Engineering boronic acid-integrated lipid nanoparticles for precision glycan-mediated gene transfer
Chakraborty, N., Sarkar, S., & Bhattacharya, S. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb00080k · Cited by 1
Therapeutic Advances in Major NBIA Disorders: Current Strategies and Translational Challenges
Cascone, F., Gasparini, G., Tiranti, V., & Meo, I. D. (2026) · Neurology International · doi:10.3390/neurolint18070133 · Cited by 1
“…gene therapy, namely gene silencing, gene replacement, gene addition, and gene editing, are based on the delivery of genetic material into the cells to replace defective genes, introduce new genes, or modify the expression of existing genes through the use of viral or non-viral vectors [162–164].”
Vasconcelos, F., & Daniel, L. (2017) · Cited by 1
Radecke, S. M., Schwarz, K., & Radecke, F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.015 · Cited by 1
Zeng, D., Lin, J., He, H., Tan, G., Lan, Y., Jiang, F., & Sheng, S. (2017) · Oncology Letters · doi:10.3892/ol.2017.7599 · Cited by 1
Expressing Full-Length Dystrophin Using Adeno-Associated Virus
Kodippili, K., & Duan, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00013-2 · Cited by 1
Characterization of CSF2A fusion gene and its effect on Epstein–Barr virus–positive tumor cells
Sun, Y., Long, J., Yin, Y., Li, H., Jiang, E., Zeng, C., & Zhu, W. (2018) · Journal of Medical Virology · doi:10.1002/jmv.25240 · Cited by 1
Komissarov, A. A., Kostrov, S. V., & Demidyuk, I. V. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8922-5_11 · Cited by 1
Implications of genome plasticity for drug development
López‐León, S., González‐Giraldo, Y., Ruiter-Lopez, L., & Wegman-Ostrosky, T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817819-5.00014-0 · Cited by 1
Research on Emerging Biotechnologies
King, N. M. P., & Coughlin, C. N. (2020) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190947750.013.29 · Cited by 1
MIP as Drug Delivery Systems for Special Application
Ma, L., & Liu, Z. (2021) · Springer eBooks · doi:10.1007/978-981-16-0227-6_9 · Cited by 2
Peptide-Modified Polycations with Acid-Triggered Lytic Activity for Efficient Gene Delivery
Cheng, Y. (2022) · Biomaterial engineering · doi:10.1007/978-981-16-5419-0_1 · Cited by 1
Identification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Radtke, S., & Kiem, H. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2679-5_6 · Cited by 1
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.